STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro et al.|Journal of Clinical Oncology|2014Cited by 60